Literature DB >> 19398421

Is inflammatory bowel disease a risk factor for early atherosclerosis?

Necati Dagli1, Orhan K Poyrazoglu, A Ferda Dagli, Fatih Sahbaz, Ilgin Karaca, M Ali Kobat, Ibrahim H Bahcecioglu.   

Abstract

OBJECTIVES: Chronic inflammatory diseases are associated with an accelerated atherosclerotic process. Recent studies have discussed whether inflammatory bowel diseases (IBDs) can predict early atherosclerosis. We investigated this possibility.
METHODS: The study consisted of IBD cases (group 1, n = 40) and healthy persons (group 2, n = 40). The IBD group was selected so as not to have vascular disease or the presence of established major cardiovascular risk factors.
RESULTS: Group 1 cases showed a significant increase in carotid intima media thickness (cIMT; P = .01). Carotid artery stiffness was impaired in group 1 (P = .03) and high-sensitivity C-reactive protein (hsCRP), homeostasis model assessment of insulin resistance (HOMA-IR), and homocysteine (Hyc) were higher in group 1 patients (P = .02, P = .03, P = .05).
CONCLUSIONS: Inflammatory bowel disease patients have an increased risk of early atherosclerosis as shown by greater values of cIMT, carotid artery stiffness, Hyc, hsCRP, and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398421     DOI: 10.1177/0003319709333869

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  31 in total

1.  Evaluation of early atherosclerosis in patients with inflammatory bowel disease.

Authors:  Hasan Kayahan; Ismail Sari; Nesat Cullu; Fahize Yuksel; Serdal Demir; Mesut Akarsu; Yigit Goktay; Belkis Unsal; Hale Akpinar
Journal:  Dig Dis Sci       Date:  2012-04-01       Impact factor: 3.199

2.  Carotid artery stiffness in Behçet's disease.

Authors:  Servet Yolbaş; Nevzat Gözel; Mustafa Necati Dağlı; Süleyman Serdar Koca; Emir Dönder
Journal:  Eur J Rheumatol       Date:  2017-06-01

Review 3.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 4.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

5.  Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Authors:  Forough Sanaee; John D Clements; Alistair W G Waugh; Richard N Fedorak; Richard Lewanczuk; Fakhreddin Jamali
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 6.  Comorbidity in inflammatory bowel disease.

Authors:  Antonio López San Román; Fernando Muñoz
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

7.  Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease.

Authors:  Ebtissam Saleh Al-Meghaiseeb; Mulfi Mubarak Al-Otaibi; Abdulrahman Al-Robayan; Reem Al-Amro; Ahmd Saad Al-Malki; Misbahul Arfin; Abdulrahman K Al-Asmari
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 8.  Risk of cardiovascular disease in inflammatory bowel disease.

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

9.  Utility of Carotid Intima-Media Thickness as an Auxiliary Vascular Parameter of Structural Alteration in Ulcerative Colitis.

Authors:  Harit Goverdhan Kothari; Sudhir Jagdishprasad Gupta; Nitin Rangrao Gaikwad
Journal:  Inflamm Intest Dis       Date:  2019-04-17

10.  Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss.

Authors:  Huaiping Yuan; Sami Zelkha; Sami Zelka; Marina Burkatovskaya; Rohit Gupte; Susan E Leeman; Salomon Amar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.